Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the management of human papillomavirus (HPV)-positive women in cervical cancer screening

American Journal of Clinical Pathology

Volumn 145, Issue 1, 2016, Pages 35-45

  Gustinucci, Daniela ^a   Rossi, Paolo Giorgi ^b   Cesarini, Elena ^a   Broccolini, Massimo ^b   Bulletti, Simonetta ^c   Carlani, Angela ^c   D'angelo, Valentina ^d   D'amico, Maria Rosaria ^d   Dato, Eugenio Di ^e   Galeazzi, Paola ^a   Malaspina, Morena ^e   Martinelli, Nadia ^c   Spita, Nicoletta ^b   Tintori, Beatrice ^a   Giaimo, Maria Donata ^a   Passamonti, Basilio ^a  

^a UO Neurologia ASL 1 Dell' Umbria Ospedale   (Italy)

^b PATHOLOGY UNIT   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d Beneficiaria di un Aiuto Individuale per la Realizzazione di Progetti di Ricerca   (Italy)

^e Servizio Prevenzione   (Italy)

Author keywords

Accuracy; Biomarkers; Cervical cancer; E6 E7 mRNA; HPV; P16INK4a; Screening

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; VAGINAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

ADULT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84954113866     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQV019     Document Type: Article

References (50)

1. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257
2. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597
3. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88
4. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1-150
5. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPVbased screening for preventing invasive cervical cancer: follow-up of European randomised controlled trials. Lancet 2014;383:524-532
6. Castle PE, Katki HA. Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol. 2010;11:214-215
7. Cuzick J, Mayrand MH, Ronco G, et al. Chapter 10: new dimensions in cervical cancer screening. Vaccine 2009;24(suppl 3):S3/90-S7
8. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(suppl 3):S3/171-S7
9. Ronco S, Accetta G, Angeloni C, et al. HTA report: Ricerca del DNA di papillomavirus umano (HPV) come test primario per lo screening dei precursori del cancro del collo uterino. Epidemiol Prev. 2012;36(3/4 suppl 1):e1-e72
10. Health Council of the Netherlands. Population Screening for Cervical Cancer. The Hague: Health Council of the Netherlands; 2011. Publication no. 2011/07E.
11. Moyer VA, US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891
12. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542
13. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol. 1999;9:405-411
14. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene. 2003;22:5201-5207
15. Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn. 2008;8:405-415
16. Lie AK, Risberg B, Borge B, et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol. 2005;97:908-915
17. Sotlar K, Stubner A, Diemer D. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol. 2004;74:107-116
18. Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007;13:2599-2605
19. Verdoodt F, Szarewski A, Halfon P, et al. Triage of women with minor abnormal cervical cytology: meta-Analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013;121:675-687
20. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229-2242
21. Benevolo M, Mottolese M, Marandino F, et al. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol. 2006;19:384-391
22. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9:937-945
23. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high grade CIN on follow up in HPV positive women according to baseline p16-INK4A results: follow up p16 NTCC. Lancet Oncol. 2013;14:168-176
24. Gustinucci D, Passamonti B, Cesarini E, et al. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomaviruspositive women within an organized cervical cancer screening program. Acta Cytol. 2012;56:506-514
25. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284
26. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-Analysis. Cancer Treat Rev. 2009;35:210-220
27. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17:2536-2545
28. GISCi, Gruppo Italiano Screening Cervicale. Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. 2010. http://www.gisci.it/documenti/documenti-gisci/documento-hpv. pdf. Accessed November 27, 2015
29. Bouvard VA, Baan RA, Straif KA, et al. Special report: policy. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009;10:321-322
30. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119
31. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013
32. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:213-220
33. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588
34. Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12:880-890
35. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774
36. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-1772
37. Zorzi M, Del Mistro A, Farruggio A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG. 2013;120:1260-1267
38. Giorgi Rossi P, Vicentini M. New cervical cancer guidelines on both sides of the Atlantic. EMJ Oncol. 2013;1:80-89
39. Bergeron C, Giorgi-Rossi P, Cas F, et al. Cytology as a triage method for HPV positive women: a sub-study nested in the NTCC randomized controlled trial. J Natl Cancer Inst. 2015;107 pii: dju423
40. US Food and Drug Administration. FDA approves first human papillomavirus test for primary cervical cancer screening. April 24, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394773.htm. AccessedMay 7, 2014
41. Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity and clinical value of HPV E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;49:2643-2650
42. Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208:184.e1-184.e11
43. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130:602-610
44. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009;339:b2569
45. Kjar SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478-1488
46. Del Mistro A, Frayle H, Ferro A, et al. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytologynegative women. J Med Screen. 2014;21:30-37
47. Confortini M, Giorgi Rossi P, Barbarino P, et al. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening program. J Med Screen. 2010;17:79-86
48. Giorgi Rossi P, Segnan N, Zappa M, et al. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer. 2007;121:2729-2734
49. Giorgi-Rossi P, Franceschi S, Ronco G. HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer. 2012;130:1387-1394
50. Waxman AG, Chelmow D.Darragh , et al. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 2012;120:1465-1471